Clinical Study

Nrg Lu-003: A Biomarker Driven Protocol For Previously Treated Alk-Mutation Positive Non-Squamous, Non-Small Cell Lung Cancer - A Nci-Nrg Alk Master Protocol

Posted Date: Feb 5, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
  • Type of Study: Drug

The purpose of this study is to assess whether ALK mutations in non-small cell lung cancers, which are usually associated with drug resistance, are prognostic for a response to ALK inhibitor therapy and to evaluate objective responses of patients with specific genetic alterations treated with crizotinib targeted therapy.


Stage Iv Alk-Positive Adenocarcinoma Non-Small Cell Lung Cancer 18 Years Or Older With Progressive Disease


Lung Cancer, Non-Small Cell Lung Cancer, Alk Mutations

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.